Pharmaceutical Strategies Group Acquires Artemetrx

Artemetrx’s unparalleled ability to provide a complete view

of total medical spend, coupled with specialized clinical outreach

programs, provides an effective tool for doing this.

. Langefeld has served the health care industry for over 30

years in executive and hands-on medical care roles.

About Pharmaceutical Strategies Group

Specialty Pharmacy Rising Costs

According to Dr. Motheral pointed out that behavioral health medications rank #1 in

terms of overall cost for many plan sponsors, and ensuring proper

utilization of these drugs is critical for effective management of

behavioral health medications as off-label drug utilization increases

nationwide. Pharmaceutical Strategies Group, LLC (

assists plan sponsors and other payors, Taft-Hartley Unions, large

employers, and health systems in designing, implementing, and managing

programs that maximize the value and impact of pharmaceuticals in their

population. Dr. “PSG’s

clients have increasingly indicated their desire to have a more

comprehensive view of patients’ clinical profiles in managing the

prescription drug benefit. Langefeld, “Greater than 50% of the specialty pharmacy

spend, the fastest growing category in terms of cost, is covered under

the medical, rather than the pharmaceutical, benefit, where it

frequently goes unmeasured and unmanaged. In addition, Artemetrx offers a suite of clinical intervention

programs that leverage the integrated data to improve care and control


Brenda Motheral, Artemetrx’s President, and Dr. Motheral brings with her more than 15 years of

experience in healthcare analytics and clinical program development,

both in the pharmacy benefits management (“PBM”) and disease management

industry. This Clinical Business

Intelligence Engine transforms the standard health data into actionable

information that is accessible through a web-based decision support

tool. This need is

particularly acute for specialty medications, where 50% or more of the

drug spend is not billed as a prescription, but as a medical claim,”

said Dave Borden, CEO of PSG.


Terms of the transaction were not disclosed.

At the core of the Artemetrx service offering is a robust proprietary

data aggregation engine that combines behavioral, medical, dental,

vision, lab, and prescription drug data to provide a comprehensive view

of health-related utilization and expenditures. Motheral said, “We are proud of having built a first class service

that combines comprehensive analytics with expert consultation related

to the pharmacy benefit. It is increasingly difficult to get a clear

picture of why a medication is being used and to capture the total cost

of care by just reviewing prescription claims data alone. We look forward to helping PSG secure its

position as the go-to pharmacy benefit management consulting firm in the


Dr. These programs range from pharmacy-centric programs to population

health programs. Dr. John Langefeld, Chief

Medical Officer. Additional news and information about Artemetrx’s

proprietary tools and clinical programs can be found at

About Artemetrx

For more information, please contact PSG at [email protected]

Artemetrx, whose technology was originally developed at the University

of Kentucky, offers data analytic tools and clinical programs that

integrate pharmacy, medical, and other healthcare information. The strategies employed by PSG consultants allow plan

sponsors to gain control over their pharmacy benefit spend, facilitate

population health management, and position their programs to

successfully negotiate the pharmacy benefit challenges of the future.

Behavioral Health Cost Containment

Joining PSG will be the senior management team of Artemetrx led by Dr. Using the Artemetrx tools and

services, PSG will now be able to provide plan sponsors with a

comprehensive view of their specialty pharmacy spend, and give them the

tools to reduce costs and implement quality of care initiatives.”

PLANO, Texas–(BUSINESS WIRE)–Pharmaceutical Strategies Group, LLC (“PSG”), America’s largest

independent pharmacy benefits consulting firm, has closed on its

acquisition of Artemetrx Health Resources, the company announced today

Leave a Reply